These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 34467825)

  • 21. How we treat advanced stage cutaneous T-cell lymphoma - mycosis fungoides and Sézary syndrome.
    Sethi TK; Montanari F; Foss F; Reddy N
    Br J Haematol; 2021 Nov; 195(3):352-364. PubMed ID: 33987825
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cutaneous T-cell lymphomas: 2023 update on diagnosis, risk-stratification, and management.
    Hristov AC; Tejasvi T; Wilcox RA
    Am J Hematol; 2023 Jan; 98(1):193-209. PubMed ID: 36226409
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic factors in 105 Japanese cases of mycosis fungoides and Sézary syndrome: clusterin expression as a novel prognostic factor.
    Tobisawa S; Honma M; Ishida-Yamamoto A; Saijo Y; Iizuka H
    J Dermatol Sci; 2013 Sep; 71(3):160-6. PubMed ID: 23702390
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical and Histological Characteristics of Mycosis Fungoides and Sézary Syndrome: A Retrospective, Single-centre Study of 43 Patients from Eastern Denmark.
    Nielsen PR; Eriksen JO; Wehkamp U; Lindahl LM; Gniadecki R; Fogh H; Fabricius S; Bzorek M; Ødum N; Gjerdrum LM
    Acta Derm Venereol; 2019 Dec; 99(13):1231-1236. PubMed ID: 31620804
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cutaneous T cell lymphomas: mycosis fungoides, Sezary syndrome and HTLV-I-associated adult T cell leukemia (ATL) in Mali, West Africa: a clinical, pathological and immunovirological study of 14 cases and a review of the African ATL cases.
    Fouchard N; Mahe A; Huerre M; Fraitag S; Valensi F; Macintyre E; Sanou F; de The G; Gessain A
    Leukemia; 1998 Apr; 12(4):578-85. PubMed ID: 9557617
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Allogeneic hematopoietic stem cell transplantation for refractory mycosis fungoides (MF) and Sezary syndrome (SS).
    Atilla E; Atilla PA; Bozdag SC; Yuksel MK; Toprak SK; Topcuoglu P; Akay BN; Sanli H; Gurman G; Ozcan M
    Int J Hematol; 2017 Sep; 106(3):426-430. PubMed ID: 28466385
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cutaneous T-cell lymphoma-Focus on some problems, and some solutions.
    Beltraminelli H
    Hematol Oncol; 2023 Jun; 41 Suppl 1():20-24. PubMed ID: 37294972
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Non-mycosis fungoides cutaneous lymphomas in a referral center in Taiwan: A retrospective case series and literature review.
    Liu KL; Tsai WC; Lee CH
    PLoS One; 2020; 15(1):e0228046. PubMed ID: 31978091
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mycosis fungoides and the Sézary syndrome: pathology, staging, and treatment.
    Hoppe RT; Wood GS; Abel EA
    Curr Probl Cancer; 1990; 14(6):293-371. PubMed ID: 2245651
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Characteristics associated with significantly worse quality of life in mycosis fungoides/Sézary syndrome from the Prospective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) study.
    Molloy K; Jonak C; Woei-A-Jin FJSH; Guenova E; Busschots AM; Bervoets A; Hauben E; Knobler R; Porkert S; Fassnacht C; Cowan R; Papadavid E; Beylot-Barry M; Berti E; Alberti Violetti S; Estrach T; Matin R; Akilov O; Vakeva L; Prince M; Bates A; Bayne M; Wachsmuch R; Wehkamp U; Marschalko M; Servitje O; Turner D; Weatherhead S; Wobser M; Sanches JA; McKay P; Klemke D; Peng C; Howles A; Yoo J; Evison F; Scarisbrick J
    Br J Dermatol; 2020 Mar; 182(3):770-779. PubMed ID: 31049926
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Characteristics and outcomes of 727 patients with mycosis fungoides and Sézary syndrome from a Brazilian cohort.
    Miyashiro D; Sanches JA
    Int J Dermatol; 2022 Apr; 61(4):442-454. PubMed ID: 34435672
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Multidisciplinary Management of Mycosis Fungoides/Sézary Syndrome.
    Berg S; Villasenor-Park J; Haun P; Kim EJ
    Curr Hematol Malig Rep; 2017 Jun; 12(3):234-243. PubMed ID: 28540671
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Heterogeneity of T-cell receptor expression at transformation in mycosis fungoides/Sezary Syndrome (MF/SS).
    Jothishankar B; Venkataraman G; Goldberg RC; Abdulla F
    Ann Diagn Pathol; 2019 Dec; 43():151404. PubMed ID: 31629155
    [No Abstract]   [Full Text] [Related]  

  • 34. Diagnosis, prognosis and management of erythrodermic cutaneous T-cell lymphoma.
    Moriarty B; Whittaker S
    Expert Rev Hematol; 2015 Apr; 8(2):159-71. PubMed ID: 25495961
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Total Skin Electron Beam for Primary Cutaneous T-cell Lymphoma.
    Elsayad K; Kriz J; Moustakis C; Scobioala S; Reinartz G; Haverkamp U; Willich N; Weishaupt C; Stadler R; Sunderkötter C; Eich HT
    Int J Radiat Oncol Biol Phys; 2015 Dec; 93(5):1077-86. PubMed ID: 26581145
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mycosis fungoides and Sézary syndrome: Australian clinical practice statement.
    Bhabha FK; McCormack C; Wells J; Campbell BA; Newland K; Lade S; Buelens O; Joske D; Shortt J; Mapp S; Radeski D; Hertzberg M; Khot A; Van Der Weyden C; Khoo C; Hawkes E; Prince HM
    Australas J Dermatol; 2021 Feb; 62(1):e8-e18. PubMed ID: 33368169
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Survival, disease progression and prognostic factors in elderly patients with mycosis fungoides and Sézary syndrome: a retrospective analysis of 174 patients.
    Lebowitz E; Geller S; Flores E; Pulitzer M; Horwitz S; Moskowitz A; Kheterpal M; Myskowski PL
    J Eur Acad Dermatol Venereol; 2019 Jan; 33(1):108-114. PubMed ID: 30176169
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Survival outcomes and prognostic factors in mycosis fungoides/Sézary syndrome: validation of the revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer staging proposal.
    Agar NS; Wedgeworth E; Crichton S; Mitchell TJ; Cox M; Ferreira S; Robson A; Calonje E; Stefanato CM; Wain EM; Wilkins B; Fields PA; Dean A; Webb K; Scarisbrick J; Morris S; Whittaker SJ
    J Clin Oncol; 2010 Nov; 28(31):4730-9. PubMed ID: 20855822
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome: clinical prognostic factors and risk for disease progression.
    Kim YH; Liu HL; Mraz-Gernhard S; Varghese A; Hoppe RT
    Arch Dermatol; 2003 Jul; 139(7):857-66. PubMed ID: 12873880
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Microenvironment's Role in Mycosis Fungoides and Sézary Syndrome: From Progression to Therapeutic Implications.
    Pileri A; Guglielmo A; Grandi V; Violetti SA; Fanoni D; Fava P; Agostinelli C; Berti E; Quaglino P; Pimpinelli N
    Cells; 2021 Oct; 10(10):. PubMed ID: 34685762
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.